Supernus Sues Actavis, Watson Over Oxtellar XR Patents

Law360, New York (August 8, 2013, 5:35 PM EDT) -- Supernus Pharmaceuticals Inc. hit Actavis Inc. and Watson Laboratories Inc. with a lawsuit in New Jersey federal court on Wednesday alleging the drugmakers are infringing two patents covering Oxtellar XR by seeking approval to sell a generic version of the anti-epileptic drug before the patents expire.

The pharmaceutical giant claims Actavis and Watson submitted an abbreviated new drug application to the U.S. Food and Drug Administration that infringes U.S. Patent Number 7,722,898 and U.S. Patent Number 7,910,131.

Both patents cover once-a-day formulations of oxcarbazepine, the active...
To view the full article, register now.